Enhancing CAR T cell effectiveness for treating acute myeloid leukemia
Official title: Improving the activity of CAR T cells for acute myeloid leukemia
Funded at Washington University · NIH-10876996 · Data updated 2026-11-12
This study is looking at how certain immune cells called myeloid cells influence the effectiveness of CAR T cell therapy for people with acute myeloid leukemia (AML), and the researchers hope to find ways to make this treatment work better for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $248,962 |
| NIH project number | 5K08CA277000-02 |
| Project ID | NIH-10876996 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research investigates how myeloid cells affect the performance of CAR T cells in treating acute myeloid leukemia (AML). The team aims to understand the interactions between CAR T cells and myeloid cells, determining how these cells can either support or hinder the effectiveness of the therapy. By using advanced techniques like viral gene transfer and CRISPR/Cas9, they will modify myeloid cells to see how these changes impact CAR T cell behavior. The goal is to improve CAR T cell therapy outcomes for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies for patients with acute myeloid leukemia.
How similar studies have gone: While CAR T cell therapies have shown success in other blood cancers, this specific approach for AML is novel and has not been extensively tested.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Kim, Miriam Y — Washington University
- Study coordinator: Kim, Miriam Y
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.